Seres Therapeutics (NASDAQ:MCRB) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a research report released on Tuesday morning.

Other equities research analysts also recently issued reports about the company. Chardan Capital reduced their price objective on Seres Therapeutics from $8.00 to $6.00 and set a buy rating for the company in a research note on Wednesday, May 8th. Canaccord Genuity Group reduced their price target on shares of Seres Therapeutics from $15.00 to $10.00 and set a buy rating for the company in a research report on Friday, June 7th. Finally, Oppenheimer reaffirmed a market perform rating on shares of Seres Therapeutics in a research report on Friday, June 7th.

Seres Therapeutics Price Performance

Seres Therapeutics stock opened at $0.98 on Tuesday. Seres Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $5.29. The firm’s 50 day simple moving average is $0.87 and its 200-day simple moving average is $0.96. The company has a market cap of $148.12 million, a P/E ratio of -1.63 and a beta of 1.98.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.09. On average, analysts expect that Seres Therapeutics will post -1.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Seres Therapeutics during the 1st quarter worth about $39,000. Tower Research Capital LLC TRC increased its holdings in Seres Therapeutics by 668.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 38,091 shares of the biotechnology company’s stock worth $53,000 after buying an additional 33,135 shares during the last quarter. SG Americas Securities LLC bought a new position in Seres Therapeutics during the fourth quarter valued at approximately $73,000. Virtu Financial LLC acquired a new stake in Seres Therapeutics in the first quarter valued at approximately $73,000. Finally, Pennant Investors LP bought a new stake in Seres Therapeutics in the fourth quarter worth approximately $409,000. Hedge funds and other institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.